



RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

JS #261D (NE)
10/7/02

PATENT

ATTORNEY DOCKET NO.: VOSS1110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Breier et al.
Serial No.: 09/445,201
Filed: April 12, 2000
Title: REGULATORY SEQUENCES CAPABLE OF CONFERRING EXPRESSION
OF A HETEROLOGOUS DNA SEQUENCE IN ENDOTHELIAL CELLS IN
VIVO AND USES THEREOF

Art Unit: 1636
Examiner: S.S. Pappu

Box AF
Commissioner for Patents
Washington, DC 20231

AMENDMENT AFTER FINAL UNDER 37 C.F.R. § 1.116

Responsive to the Office Action mailed April 23, 2002, entry of the amendments and reconsideration of the application in view of the amendments and the following remarks respectfully are requested.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, September 23, 2002, in an envelope addressed to: Box AF, Commissioner for Patents, Washington, DC 20231.	
Aldon Griffis (Name of Person Mailing Paper)	
 (Signature)	September 23, 2002 (Date)

I. AMENDMENTS

In the Claims

Please cancel claims 12, 14, 15, 16, 25-33, and 36-41, without prejudice.

Please amend the claim to read as follows:

1. (Twice Amended) A recombinant DNA molecule comprising:

(a) at least one first regulatory sequence which confers expression in endothelial cells *in vivo*, wherein said first regulatory sequence is selected from the group consisting of

(i) a DNA sequence comprising a nucleotide sequence as given in SEQ ID NO: 1;

(ii) a DNA sequence comprising a nucleotide sequence of SEQ ID NO: 1 from nucleotide 8260 to nucleotide 10560, from nucleotide 8336 to nucleotide 10608 and/or from nucleotide 10094 to nucleotide 10608; and

(iii) a DNA sequence comprising a fragment of a nucleotide sequence of (i) or (ii); and

(b) operatively linked thereto a heterologous DNA sequence.